These results demonstrate that Lu AG09222 binds to and effectively inhibits PACAP38-mediated physiological responses and indicate Lu AG09222 as a future treatment for migraine and other conditions that would benefit from inhibition of the PACAP signalling cascade. The gene discussed is ADCYAP1; the disease is migraine disorder.